Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Inclusion Criteria: * Clinically confirmed no evidence of disease \>= 90 days from completion of systemic therapy with the exception of hormonal therapy and bisphosphonates (per practice guidelines for breast and ovarian cancer) * Histological or cytological confirmation of stage II or III breast cancer or stage II, III, or IV ovarian/primary peritoneal/fallopian tube cancer; Note: patients with stage IV ovarian/primary peritoneal/fallopian tube cancer must register within one year of completing chemotherapy * Completed systemic treatment (chemotherapy, immune modulators \[such as trastuzumab\], radiation, and/or corticosteroids) with the exception of hormonal therapy and bisphosphonates \>= 90 days prior to registration * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 * Absolute neutrophil count (ANC) \>= 1500/mm\^3 * Platelets \>= 100,000/ul * Hemoglobin \>= 10.0 g/dL * Creatinine =\< 1.5 x upper limit of normal (ULN) or 24 hour urine =\< grade 2 * Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) =\< 3 x ULN * Serum albumin \>= 3 g/dL * Urinalysis with =\< 2+ proteinuria * Thyroid-stimulating hormone (TSH) - negative or =\< normal institutional range * Anti-nuclear antibody (ANA) - negative or =\< normal institutional range * Serum rheumatoid factor (RF) - negative or =\< normal institutional range * Negative serum pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only * Ca…